For Healthcare Professionals Outside the US
DoR, duration of response; IRC, independent review committee; NA, not available; NE, not evaluable; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.
References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial [published online September 8, 2017]. Lancet Oncol. doi:10.1016/S1470-2045(17)30679-4.